The purpose of this study is to collect and analyze data in patients with inflammatory bowel disease (IBD) who are currently receiving IBD medication(s) that targets their immune system (targeted immunomodulator- TIM) in routine clinical care and are feeling well but have active inflammation on colonoscopy. The study aims to determine whether switching to an alternative IBD medication will improve disease outcome without increasing the burden of treatment. IBD, including ulcerative colitis and Crohn’s disease, is a chronic condition that causes inflammation of the intestinal tract. Treatment of IBD often involves long-term use of TIM therapies. This study is proposing a “treat-to-target” approach, in which treatment strategies aim to resolve bowel inflammation by switching to another TIM in patients without symptoms but with bowel inflammation in the hope of achieving endoscopic remission. Endoscopic remission may, in turn, decrease the risk of relapse, unplanned healthcare utilization, IBD-related disability, and improve quality of life, versus continuing current TIM therapy.
What is the full name of this clinical trial?
Treat-to-Target of Endoscopic Remission in Patients with IBD in Symptomatic Remission: The QUOTIENT Trial
Inflammatory Bowel Disease
Andrea Banty, Gaurav Syal, Susie Lee